Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1101 of 5804
-
Can a chat program help young smokers quit for good?
Disease control Recruiting nowThe health benefits of smoking cessation by age 30 are much greater than cessation later in life, including gaining 10 years of life, compared with those who continue to smoke. The goal of the proposed study is to evaluate the effectiveness of the bilingual and culturally tailore…
Phase: NA • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New program bridges schools and clinics to tame childhood asthma
Disease control Recruiting nowThe overall goal of this research study is to evaluate a multi-level program called PRAGMATIC-S to improve the delivery of guideline-based asthma care through a unique partnership between clinical practices and schools. PRAGMATIC-S represents a novel approach that addresses multi…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New lupus drug candidate D-2570 enters Mid-Stage trial
Disease control Recruiting nowThis study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.
Phase: PHASE2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a tiny dose of a diabetes drug stop weight regain in HIV patients?
Disease control Recruiting nowThe objectives of this study are as follows: Primary Objective * To determine the rate of weight regain in people living with human immunodeficiency virus (HIV) (PWH) receiving semaglutide microdosing vs. no additional drug following induction therapy. Secondary Objectives * …
Phase: PHASE2 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for ovarian cancer: personalized cell therapy enters human trials
Disease control Recruiting nowSafety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer
Phase: PHASE1 • Sponsor: PhotonPharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can red light stop severe nearsightedness from worsening in adults?
Disease control Not yet recruitingThis study, led by Jie ying from the Ophthalmology Department of Beijing Tongren Hospital Affiliated to Capital Medical University, is a researcher-initiated clinical trial (IIT) designed to evaluate the therapeutic efficacy of low-intensity red light therapy in adult patients wi…
Phase: NA • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo therapy aims to improve sarcoma surgery outcomes
Disease control Not yet recruitingTo investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy combined with immunotherapy followed by surgery for retroperitoneal sarcoma
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Engineered immune cells take on pancreatic cancer in early trial
Disease control Recruiting nowThis is a single-center, open-label, first-in-human, fixed-dose study in patients with pancreatic cancer.
Phase: PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New pill targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingEvaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Smart robotic hand learns to grip objects for amputees
Disease control OngoingThe purpose of this research is to create an intelligent robotic hand for people who have lost a limb below their elbow. By using artificial intelligence to adaptively grasp different types of objects, this will improve both the accuracy and flexibility of robotic prosthetic cont…
Phase: NA • Sponsor: Al-Nahrain University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for rare penile cancer: targeted drug combo shows promise
Disease control Recruiting nowPenile squamous cell carcinoma (PSCC) is a rare malignancy, with stage IV patients exhibiting a 2-year overall survival (OS) rate of 21% and a 5-year survival rate of 0%. Both the National Comprehensive Cancer Network (NCCN) and European Association of Urology (EAU) guidelines re…
Phase: PHASE1 • Sponsor: Jiyan Liu • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New smart drug takes aim at Hard-to-Treat brain cancers
Disease control Recruiting nowThis will be an open-label Phase 0/1 study that will enroll approximately 15 participants, 9 participants with recurrent WHO Grade 4 glioma (rGBM) and 6 participants with brain metastases, who will receive the investigational drug risvutatug rezetecan (GSK5764227), a B7-H3-target…
Phase: EARLY_PHASE1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Ear nerve stimulator could tame Kids' vomiting episodes
Symptom relief Recruiting nowCyclic vomiting syndrome (CVS) is a fairly common disorder characterized by relentless episodes of vomiting followed by return to baseline health.The majority of children with CVS have concurrent severe abdominal pain and migraine-features, causing significant disability during t…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Experimental drug cocktail takes on Hard-to-Treat cancers
Disease control Recruiting nowThis study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.
Phase: PHASE1, PHASE2 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Underwater adventure could replace needles for Kids' MRI scans
Symptom relief Recruiting nowMagnetic resonance imaging (MRI) is a common imaging procedure that is safe and non-invasive, as it relies on the use of different magnetic fields. It is the gold standard examination for a wide range of pathologies. However, it has many disadvantages, including the repetitive n…
Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New trial tests if adding a blood thinner to standard care prevents heart attacks in rare artery condition
Disease control Recruiting nowCoronary artery ectasia (CAE) is a condition in which a coronary artery becomes abnormally dilated, measuring at least 50% larger than the adjacent normal segment. Although relatively uncommon, CAE is clinically important because it can lead to abnormal blood flow and increase th…
Phase: PHASE4 • Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a lymphatic bypass surgery soothe diabetic nerve damage?
Disease control ENROLLING_BY_INVITATIONDiabetes is a metabolic disease characterized by high blood sugar levels due to a lack of insulin. Long-term metabolic disorders can cause structural and functional changes in many organs, mainly affecting the vascular system, and leading to complications in the eyes, kidneys, an…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo aims to revive immunotherapy in resistant cancers
Disease control Recruiting nowThis is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1/PD-L1 inhibitors in patients with tumors refractory to PD-1/PD-L1 inhibitors, for which such treatments have been approved.
Phase: PHASE1 • Sponsor: Mohammed Milhem • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to wipe out hidden colorectal cancer cells
Disease control TerminatedTo learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail aims to keep prostate cancer away after surgery
Disease control Not yet recruitingThe goal of this clinical trial is to learn if Rezvilutamide works to treat high-risk prostate cancer in patients who have recently undergone surgery (radical prostatectomy). It will also learn about the safety of Rezvilutamide. The main questions it aims to answer are: Does Rez…
Phase: NA • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC